The global market for Monoclonal Antibody for Asthma and COPD was valued at US$ 32163 million in the year 2024 and is projected to reach a revised size of US$ 47528 million by 2031, growing at a CAGR of 5.6% during the forecast period.

Monoclonal Antibody for Asthma and COPD Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Monoclonal Antibody for Asthma and COPD competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Monoclonal antibodies for asthma and COPD are biologic agents targeting specific inflammatory pathways, neutralizing particular cytokines or receptors to modulate immune responses and improve airway inflammation and function. Representative drugs include Omalizumab, Mepolizumab, and Benralizumab, primarily used for the long-term management of patients with severe asthma, eosinophilic asthma, and certain COPD phenotypes. Upstream raw materials consist of high-purity recombinant antibody proteins, mammalian expression systems such as CHO cells, recombinant gene fragments, and associated buffers and excipients. Leading global suppliers include Biogen, Genentech (Roche), Amgen, GlaxoSmithKline (GSK), AstraZeneca, and Novartis, all of which possess advanced capabilities in antibody expression, purification, and large-scale manufacturing.

Downstream customers mainly comprise global pharmaceutical companies, hospitals, specialty clinics, and retail pharmacies, targeting patients with chronic respiratory diseases requiring long-term treatment. The primary end-users are patients with moderate-to-severe asthma or specific COPD phenotypes, as well as specialized respiratory medical institutions. With continuous advancements in biopharmaceutical technology and precision medicine, monoclonal antibody therapies are optimized for efficacy and safety, simultaneously driving upstream and downstream sectors, including expression system development, purification and fill-finish processes, cold-chain logistics, and clinical management services, thereby forming a complete high-value industrial ecosystem.

In 2024, the global average price of monoclonal antibodies for asthma and COPD is approximately USD 1,031 per vial, with total sales reaching about 31.2 million vials.

North American market for Monoclonal Antibody for Asthma and COPD is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Monoclonal Antibody for Asthma and COPD is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Monoclonal Antibody for Asthma and COPD include Teva Pharmaceuticals, Sanofi, AstraZeneca, GlaxoSmithKline, Roche, Amgen, Abacus Medicine, Swixx Biopharma, OriFarm, Aphria, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Monoclonal Antibody for Asthma and COPD, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Monoclonal Antibody for Asthma and COPD.

The Monoclonal Antibody for Asthma and COPD market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Monoclonal Antibody for Asthma and COPD market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Monoclonal Antibody for Asthma and COPD manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Monoclonal Antibody for Asthma and COPD Market Report

Report Metric	Details
Report Name	Monoclonal Antibody for Asthma and COPD Market
Accounted market size in year	US$ 32163 million
Forecasted market size in 2031	US$ 47528 million
CAGR	5.6%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Reslizumab Dupilumab Benralizumab Mepolizumab Tezepelumab-ekko Omalizumab Others
Segment by Application	Hospital Clinic Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Teva Pharmaceuticals, Sanofi, AstraZeneca, GlaxoSmithKline, Roche, Amgen, Abacus Medicine, Swixx Biopharma, OriFarm, Aphria, Novartis
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Monoclonal Antibody for Asthma and COPD manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Monoclonal Antibody for Asthma and COPD in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Monoclonal Antibody for Asthma and COPD Market growing?

Ans: The Monoclonal Antibody for Asthma and COPD Market witnessing a CAGR of 5.6% during the forecast period 2025-2031.

What is the Monoclonal Antibody for Asthma and COPD Market size in 2031?

Ans: The Monoclonal Antibody for Asthma and COPD Market size in 2031 will be US$ 47528 million.

Who are the main players in the Monoclonal Antibody for Asthma and COPD Market report?

Ans: The main players in the Monoclonal Antibody for Asthma and COPD Market are Teva Pharmaceuticals, Sanofi, AstraZeneca, GlaxoSmithKline, Roche, Amgen, Abacus Medicine, Swixx Biopharma, OriFarm, Aphria, Novartis

What are the Application segmentation covered in the Monoclonal Antibody for Asthma and COPD Market report?

Ans: The Applications covered in the Monoclonal Antibody for Asthma and COPD Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Monoclonal Antibody for Asthma and COPD Market report?

Ans: The Types covered in the Monoclonal Antibody for Asthma and COPD Market report are Reslizumab, Dupilumab, Benralizumab, Mepolizumab, Tezepelumab-ekko, Omalizumab, Others

1 Monoclonal Antibody for Asthma and COPD Market Overview

1.1 Product Definition

1.2 Monoclonal Antibody for Asthma and COPD by Type

1.2.1 Global Monoclonal Antibody for Asthma and COPD Market Value Comparison by Type (2024 VS 2031)

1.2.2 Reslizumab

1.2.3 Dupilumab

1.2.4 Benralizumab

1.2.5 Mepolizumab

1.2.6 Tezepelumab-ekko

1.2.7 Omalizumab

1.2.8 Others

1.3 Monoclonal Antibody for Asthma and COPD by Application

1.3.1 Global Monoclonal Antibody for Asthma and COPD Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global Monoclonal Antibody for Asthma and COPD Market Size Estimates and Forecasts

1.4.1 Global Monoclonal Antibody for Asthma and COPD Revenue 2020-2031

1.4.2 Global Monoclonal Antibody for Asthma and COPD Sales 2020-2031

1.4.3 Global Monoclonal Antibody for Asthma and COPD Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Monoclonal Antibody for Asthma and COPD Market Competition by Manufacturers

2.1 Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Manufacturers (2020-2025)

2.2 Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Monoclonal Antibody for Asthma and COPD Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Monoclonal Antibody for Asthma and COPD, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Product Type & Application

2.7 Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Date of Enter into This Industry

2.8 Global Monoclonal Antibody for Asthma and COPD Market Competitive Situation and Trends

2.8.1 Global Monoclonal Antibody for Asthma and COPD Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Monoclonal Antibody for Asthma and COPD Players Market Share by Revenue

2.8.3 Global Monoclonal Antibody for Asthma and COPD Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Monoclonal Antibody for Asthma and COPD Market Scenario by Region

3.1 Global Monoclonal Antibody for Asthma and COPD Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Monoclonal Antibody for Asthma and COPD Sales by Region: 2020-2031

3.2.1 Global Monoclonal Antibody for Asthma and COPD Sales by Region: 2020-2025

3.2.2 Global Monoclonal Antibody for Asthma and COPD Sales by Region: 2026-2031

3.3 Global Monoclonal Antibody for Asthma and COPD Revenue by Region: 2020-2031

3.3.1 Global Monoclonal Antibody for Asthma and COPD Revenue by Region: 2020-2025

3.3.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Region: 2026-2031

3.4 North America Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Country

3.4.1 North America Monoclonal Antibody for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2031)

3.4.3 North America Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Country

3.5.1 Europe Monoclonal Antibody for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2031)

3.5.3 Europe Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Region

3.6.1 Asia Pacific Monoclonal Antibody for Asthma and COPD Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Monoclonal Antibody for Asthma and COPD Sales by Region (2020-2031)

3.6.3 Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Country

3.7.1 Latin America Monoclonal Antibody for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2031)

3.7.3 Latin America Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Monoclonal Antibody for Asthma and COPD Market Facts & Figures by Country

3.8.1 Middle East and Africa Monoclonal Antibody for Asthma and COPD Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2031)

3.8.3 Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Monoclonal Antibody for Asthma and COPD Sales by Type (2020-2031)

4.1.1 Global Monoclonal Antibody for Asthma and COPD Sales by Type (2020-2025)

4.1.2 Global Monoclonal Antibody for Asthma and COPD Sales by Type (2026-2031)

4.1.3 Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2020-2031)

4.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Type (2020-2031)

4.2.1 Global Monoclonal Antibody for Asthma and COPD Revenue by Type (2020-2025)

4.2.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Type (2026-2031)

4.2.3 Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Type (2020-2031)

4.3 Global Monoclonal Antibody for Asthma and COPD Price by Type (2020-2031)

5 Segment by Application

5.1 Global Monoclonal Antibody for Asthma and COPD Sales by Application (2020-2031)

5.1.1 Global Monoclonal Antibody for Asthma and COPD Sales by Application (2020-2025)

5.1.2 Global Monoclonal Antibody for Asthma and COPD Sales by Application (2026-2031)

5.1.3 Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Application (2020-2031)

5.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Application (2020-2031)

5.2.1 Global Monoclonal Antibody for Asthma and COPD Revenue by Application (2020-2025)

5.2.2 Global Monoclonal Antibody for Asthma and COPD Revenue by Application (2026-2031)

5.2.3 Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Application (2020-2031)

5.3 Global Monoclonal Antibody for Asthma and COPD Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Teva Pharmaceuticals

6.1.1 Teva Pharmaceuticals Company Information

6.1.2 Teva Pharmaceuticals Description and Business Overview

6.1.3 Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Product Portfolio

6.1.5 Teva Pharmaceuticals Recent Developments/Updates

6.2 Sanofi

6.2.1 Sanofi Company Information

6.2.2 Sanofi Description and Business Overview

6.2.3 Sanofi Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Sanofi Monoclonal Antibody for Asthma and COPD Product Portfolio

6.2.5 Sanofi Recent Developments/Updates

6.3 AstraZeneca

6.3.1 AstraZeneca Company Information

6.3.2 AstraZeneca Description and Business Overview

6.3.3 AstraZeneca Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)

6.3.4 AstraZeneca Monoclonal Antibody for Asthma and COPD Product Portfolio

6.3.5 AstraZeneca Recent Developments/Updates

6.4 GlaxoSmithKline

6.4.1 GlaxoSmithKline Company Information

6.4.2 GlaxoSmithKline Description and Business Overview

6.4.3 GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)

6.4.4 GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Product Portfolio

6.4.5 GlaxoSmithKline Recent Developments/Updates

6.5 Roche

6.5.1 Roche Company Information

6.5.2 Roche Description and Business Overview

6.5.3 Roche Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Roche Monoclonal Antibody for Asthma and COPD Product Portfolio

6.5.5 Roche Recent Developments/Updates

6.6 Amgen

6.6.1 Amgen Company Information

6.6.2 Amgen Description and Business Overview

6.6.3 Amgen Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Amgen Monoclonal Antibody for Asthma and COPD Product Portfolio

6.6.5 Amgen Recent Developments/Updates

6.7 Abacus Medicine

6.7.1 Abacus Medicine Company Information

6.7.2 Abacus Medicine Description and Business Overview

6.7.3 Abacus Medicine Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Abacus Medicine Monoclonal Antibody for Asthma and COPD Product Portfolio

6.7.5 Abacus Medicine Recent Developments/Updates

6.8 Swixx Biopharma

6.8.1 Swixx Biopharma Company Information

6.8.2 Swixx Biopharma Description and Business Overview

6.8.3 Swixx Biopharma Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Swixx Biopharma Monoclonal Antibody for Asthma and COPD Product Portfolio

6.8.5 Swixx Biopharma Recent Developments/Updates

6.9 OriFarm

6.9.1 OriFarm Company Information

6.9.2 OriFarm Description and Business Overview

6.9.3 OriFarm Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)

6.9.4 OriFarm Monoclonal Antibody for Asthma and COPD Product Portfolio

6.9.5 OriFarm Recent Developments/Updates

6.10 Aphria

6.10.1 Aphria Company Information

6.10.2 Aphria Description and Business Overview

6.10.3 Aphria Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Aphria Monoclonal Antibody for Asthma and COPD Product Portfolio

6.10.5 Aphria Recent Developments/Updates

6.11 Novartis

6.11.1 Novartis Company Information

6.11.2 Novartis Description and Business Overview

6.11.3 Novartis Monoclonal Antibody for Asthma and COPD Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Novartis Monoclonal Antibody for Asthma and COPD Product Portfolio

6.11.5 Novartis Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Monoclonal Antibody for Asthma and COPD Industry Chain Analysis

7.2 Monoclonal Antibody for Asthma and COPD Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Monoclonal Antibody for Asthma and COPD Production Mode & Process Analysis

7.4 Monoclonal Antibody for Asthma and COPD Sales and Marketing

7.4.1 Monoclonal Antibody for Asthma and COPD Sales Channels

7.4.2 Monoclonal Antibody for Asthma and COPD Distributors

7.5 Monoclonal Antibody for Asthma and COPD Customer Analysis

8 Monoclonal Antibody for Asthma and COPD Market Dynamics

8.1 Monoclonal Antibody for Asthma and COPD Industry Trends

8.2 Monoclonal Antibody for Asthma and COPD Market Drivers

8.3 Monoclonal Antibody for Asthma and COPD Market Challenges

8.4 Monoclonal Antibody for Asthma and COPD Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Monoclonal Antibody for Asthma and COPD Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Monoclonal Antibody for Asthma and COPD Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Monoclonal Antibody for Asthma and COPD Market Competitive Situation by Manufacturers in 2024

Table 4. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Monoclonal Antibody for Asthma and COPD Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Monoclonal Antibody for Asthma and COPD Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Monoclonal Antibody for Asthma and COPD, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Product Type & Application

Table 12. Global Key Manufacturers of Monoclonal Antibody for Asthma and COPD, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Monoclonal Antibody for Asthma and COPD by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Monoclonal Antibody for Asthma and COPD as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Monoclonal Antibody for Asthma and COPD Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Monoclonal Antibody for Asthma and COPD Sales by Region (2020-2025) & (K Units)

Table 18. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Region (2020-2025)

Table 19. Global Monoclonal Antibody for Asthma and COPD Sales by Region (2026-2031) & (K Units)

Table 20. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Region (2026-2031)

Table 21. Global Monoclonal Antibody for Asthma and COPD Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Region (2020-2025)

Table 23. Global Monoclonal Antibody for Asthma and COPD Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Region (2026-2031)

Table 25. North America Monoclonal Antibody for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2025) & (K Units)

Table 27. North America Monoclonal Antibody for Asthma and COPD Sales by Country (2026-2031) & (K Units)

Table 28. North America Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Monoclonal Antibody for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Monoclonal Antibody for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2025) & (K Units)

Table 32. Europe Monoclonal Antibody for Asthma and COPD Sales by Country (2026-2031) & (K Units)

Table 33. Europe Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Monoclonal Antibody for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Monoclonal Antibody for Asthma and COPD Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Monoclonal Antibody for Asthma and COPD Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Monoclonal Antibody for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Monoclonal Antibody for Asthma and COPD Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Monoclonal Antibody for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Monoclonal Antibody for Asthma and COPD Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Monoclonal Antibody for Asthma and COPD Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) by Type (2020-2025)

Table 51. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) by Type (2026-2031)

Table 52. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2020-2025)

Table 53. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Type (2026-2031)

Table 54. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Type (2020-2025)

Table 57. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Type (2026-2031)

Table 58. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Type (2020-2025)

Table 59. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Type (2026-2031)

Table 60. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) by Application (2020-2025)

Table 61. Global Monoclonal Antibody for Asthma and COPD Sales (K Units) by Application (2026-2031)

Table 62. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Application (2020-2025)

Table 63. Global Monoclonal Antibody for Asthma and COPD Sales Market Share by Application (2026-2031)

Table 64. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Monoclonal Antibody for Asthma and COPD Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Application (2020-2025)

Table 67. Global Monoclonal Antibody for Asthma and COPD Revenue Market Share by Application (2026-2031)

Table 68. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Application (2020-2025)

Table 69. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Application (2026-2031)

Table 70. Teva Pharmaceuticals Company Information

Table 71. Teva Pharmaceuticals Description and Business Overview

Table 72. Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Teva Pharmaceuticals Monoclonal Antibody for Asthma and COPD Product

Table 74. Teva Pharmaceuticals Recent Developments/Updates

Table 75. Sanofi Company Information

Table 76. Sanofi Description and Business Overview

Table 77. Sanofi Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Sanofi Monoclonal Antibody for Asthma and COPD Product

Table 79. Sanofi Recent Developments/Updates

Table 80. AstraZeneca Company Information

Table 81. AstraZeneca Description and Business Overview

Table 82. AstraZeneca Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. AstraZeneca Monoclonal Antibody for Asthma and COPD Product

Table 84. AstraZeneca Recent Developments/Updates

Table 85. GlaxoSmithKline Company Information

Table 86. GlaxoSmithKline Description and Business Overview

Table 87. GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. GlaxoSmithKline Monoclonal Antibody for Asthma and COPD Product

Table 89. GlaxoSmithKline Recent Developments/Updates

Table 90. Roche Company Information

Table 91. Roche Description and Business Overview

Table 92. Roche Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Roche Monoclonal Antibody for Asthma and COPD Product

Table 94. Roche Recent Developments/Updates

Table 95. Amgen Company Information

Table 96. Amgen Description and Business Overview

Table 97. Amgen Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Amgen Monoclonal Antibody for Asthma and COPD Product

Table 99. Amgen Recent Developments/Updates

Table 100. Abacus Medicine Company Information

Table 101. Abacus Medicine Description and Business Overview

Table 102. Abacus Medicine Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Abacus Medicine Monoclonal Antibody for Asthma and COPD Product

Table 104. Abacus Medicine Recent Developments/Updates

Table 105. Swixx Biopharma Company Information

Table 106. Swixx Biopharma Description and Business Overview

Table 107. Swixx Biopharma Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Swixx Biopharma Monoclonal Antibody for Asthma and COPD Product

Table 109. Swixx Biopharma Recent Developments/Updates

Table 110. OriFarm Company Information

Table 111. OriFarm Description and Business Overview

Table 112. OriFarm Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. OriFarm Monoclonal Antibody for Asthma and COPD Product

Table 114. OriFarm Recent Developments/Updates

Table 115. Aphria Company Information

Table 116. Aphria Description and Business Overview

Table 117. Aphria Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 118. Aphria Monoclonal Antibody for Asthma and COPD Product

Table 119. Aphria Recent Developments/Updates

Table 120. Novartis Company Information

Table 121. Novartis Description and Business Overview

Table 122. Novartis Monoclonal Antibody for Asthma and COPD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 123. Novartis Monoclonal Antibody for Asthma and COPD Product

Table 124. Novartis Recent Developments/Updates

Table 125. Key Raw Materials Lists

Table 126. Raw Materials Key Suppliers Lists

Table 127. Monoclonal Antibody for Asthma and COPD Distributors List

Table 128. Monoclonal Antibody for Asthma and COPD Customers List

Table 129. Monoclonal Antibody for Asthma and COPD Market Trends

Table 130. Monoclonal Antibody for Asthma and COPD Market Drivers

Table 131. Monoclonal Antibody for Asthma and COPD Market Challenges

Table 132. Monoclonal Antibody for Asthma and COPD Market Restraints

Table 133. Research Programs/Design for This Report

Table 134. Key Data Information from Secondary Sources

Table 135. Key Data Information from Primary Sources

Table 136. Authors List of This Report

List of Figures

Figure 1. Product Picture of Monoclonal Antibody for Asthma and COPD

Figure 2. Global Monoclonal Antibody for Asthma and COPD Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Monoclonal Antibody for Asthma and COPD Market Share by Type: 2024 & 2031

Figure 4. Reslizumab Product Picture

Figure 5. Dupilumab Product Picture

Figure 6. Benralizumab Product Picture

Figure 7. Mepolizumab Product Picture

Figure 8. Tezepelumab-ekko Product Picture

Figure 9. Omalizumab Product Picture

Figure 10. Others Product Picture

Figure 11. Global Monoclonal Antibody for Asthma and COPD Market Value by Application (2020-2031) & (US$ Million)

Figure 12. Global Monoclonal Antibody for Asthma and COPD Market Share by Application: 2024 & 2031

Figure 13. Hospital

Figure 14. Clinic

Figure 15. Others

Figure 16. Global Monoclonal Antibody for Asthma and COPD Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 17. Global Monoclonal Antibody for Asthma and COPD Market Size (2020-2031) & (US$ Million)

Figure 18. Global Monoclonal Antibody for Asthma and COPD Sales (2020-2031) & (K Units)

Figure 19. Global Monoclonal Antibody for Asthma and COPD Average Price (US$/Unit) & (2020-2031)

Figure 20. Monoclonal Antibody for Asthma and COPD Report Years Considered

Figure 21. Monoclonal Antibody for Asthma and COPD Sales Share by Manufacturers in 2024

Figure 22. Global Monoclonal Antibody for Asthma and COPD Revenue Share by Manufacturers in 2024

Figure 23. Global 5 and 10 Largest Monoclonal Antibody for Asthma and COPD Players: Market Share by Revenue in Monoclonal Antibody for Asthma and COPD in 2024

Figure 24. Monoclonal Antibody for Asthma and COPD Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 25. Global Monoclonal Antibody for Asthma and COPD Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 26. North America Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2020-2031)

Figure 27. North America Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2020-2031)

Figure 28. United States Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Canada Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Europe Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2020-2031)

Figure 31. Europe Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2020-2031)

Figure 32. Germany Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. France Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. U.K. Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Italy Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Russia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Asia Pacific Monoclonal Antibody for Asthma and COPD Sales Market Share by Region (2020-2031)

Figure 38. Asia Pacific Monoclonal Antibody for Asthma and COPD Revenue Market Share by Region (2020-2031)

Figure 39. China Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Japan Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. South Korea Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. India Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Australia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. China Taiwan Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Southeast Asia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Latin America Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2020-2031)

Figure 47. Latin America Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2020-2031)

Figure 48. Mexico Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Brazil Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Argentina Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Colombia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. Middle East and Africa Monoclonal Antibody for Asthma and COPD Sales Market Share by Country (2020-2031)

Figure 53. Middle East and Africa Monoclonal Antibody for Asthma and COPD Revenue Market Share by Country (2020-2031)

Figure 54. Turkey Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Saudi Arabia Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. UAE Monoclonal Antibody for Asthma and COPD Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 57. Global Sales Market Share of Monoclonal Antibody for Asthma and COPD by Type (2020-2031)

Figure 58. Global Revenue Market Share of Monoclonal Antibody for Asthma and COPD by Type (2020-2031)

Figure 59. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Type (2020-2031)

Figure 60. Global Sales Market Share of Monoclonal Antibody for Asthma and COPD by Application (2020-2031)

Figure 61. Global Revenue Market Share of Monoclonal Antibody for Asthma and COPD by Application (2020-2031)

Figure 62. Global Monoclonal Antibody for Asthma and COPD Price (US$/Unit) by Application (2020-2031)

Figure 63. Monoclonal Antibody for Asthma and COPD Value Chain

Figure 64. Channels of Distribution (Direct Vs Distribution)

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-10M17946

Fri Sep 26 00:00:00 UTC 2025

Add to Cart

Global Respiratory Distress Syndrome Management Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-28H19632

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Asthma Monitoring Software Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-5Y16546

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

Global Respiratory Disease Test Kit Market Research Report 2025

120 Pages

Type: Report

Code: QYRE-Auto-2Q16721

Thu Sep 25 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Monoclonal Antibody for Asthma and COPD Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-3C19957

Global Monoclonal Antibody for Asthma and COPD Market Research Report 2025

FEATURED COMPANIES

Monoclonal Antibody for Asthma and COPD Market Size

Monoclonal Antibody for Asthma and COPD Market

Report Scope

Scope of Monoclonal Antibody for Asthma and COPD Market Report

Core Chapters

FAQ for this report

How fast is Monoclonal Antibody for Asthma and COPD Market growing?

What is the Monoclonal Antibody for Asthma and COPD Market size in 2031?

Who are the main players in the Monoclonal Antibody for Asthma and COPD Market report?

What are the Application segmentation covered in the Monoclonal Antibody for Asthma and COPD Market report?

What are the Type segmentation covered in the Monoclonal Antibody for Asthma and COPD Market report?

FEATURED COMPANIES

RELATED REPORTS